WebLi et al. identified DRAK2 as a novel and essential regulator of nonalcoholic steatohepatitis (NASH). DRAK2 promotes NASH via directly interacting with SRSF6 to … WebDRAK2 promotes NASH via directly interacting with SRSF6 to inhibit its phosphorylation by SRPK1 and regulate alternative splicing of mitochondrial function-related genes.
DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2 …
Web8 dic 2024 · These results further indicate the therapeutic potential of targeting the DRAK2-SRSF6 signaling pathway in the amelioration of the continuum of NAFLD/NASH … WebDrak2, a serine-threonine kinase, expressed abundantly in T and B cells, is a negative regulator of T cell activation. However, unlike other negative regulators, Drak2 plays an important role in eliciting autoimmunity, rather than preventing it. podiatrist in hilton head
Mitochondria homeostasis: Biology and involvement in hepatic
WebDRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH [2024 ] ... "DRAK2-SRSF6-regulated RNA alternative splicing is a … Web26 gen 2024 · Death-associated protein kinase-related apoptosis-inducing protein kinase 2 (DRAK2) has become a promising target for drug development. In search of novel and selective DRAK2 inhibitor motif, in vitro screen kinase assay was established performed using in-house chemical libraries. Web7 gen 2015 · Drak2 is a serine/threonine kinase expressed highest in B cells and T cells ( 1–3 ). In the absence of Drak2, mice are resistant to autoimmune disease in models of type 1 diabetes and multiple sclerosis ( 1, 4 ). In addition, Drak2−/− mice display increased survival of tissue grafts in organ transplant models ( 5 ). podiatrist in high point nc